Literature DB >> 2384100

Biodistribution in normal mice of an 111In-labelled prostatic acid phosphatase-specific antibody and its F(ab')2 fragments derivatized site-specifically or via bicyclic diethylenetriaminepentaacetic acid anhydride.

M Perälä1, P Vihko, M Södervall, J Heikkilä, R Vihko.   

Abstract

In this study we examined optimization of derivatization of monoclonal antibodies and their fragments intended for use as radiopharmaceutical in radioimaging and/or radioimmunotherapy of prostatic cancer. Two different principles were used to conjugate diethylenetriaminepentaacetic acid (DTPA) to a monoclonal antibody (Mab, subclass IgG1) raised against human prostatic acid phosphatase (PAP). In addition, the F(ab')2 fragments of this Mab were also derivatized. We used the cyclic anhydride of DTPA (CA-DTPA) as a chelating agent for these two protein moieties. Furthermore, the Mab and the F(ab')2 fragments were modified site-specifically by attaching linkers, N-(p-aminobenzyl)diethylenetriaminetetraacetic acid (p-NH2-Bz-DTTA) and 1-(p-aminobenzyl)diethylenetriaminepentaacetic acid (p-NH2-Bz-DTPA), to the carbohydrate components of the parent molecules. In this study, biodistribution of the 111In-labelled derivatives was investigated in normal mice. All the derivatives of IgG1 demonstrated a slower blood clearance than the corresponding derivatives of the F(ab')2 fragments. This property was particularly pronounced in the site-specifically conjugated derivatives of IgG1. All the derivatives studied accumulated in the liver, kidney, and spleen. The CA-DTPA derivatives of F(ab')2 fragments showed the highest kidney-to-blood ratios of radioactivity compared with the other compounds studied. The derivatives of IgG1 showed a higher percentage of the injected dose in liver and spleen tissues than the derivatives of the F(ab')2 fragments. The F(ab')2 fragments studied also gave rise to site-specific derivatives, which demonstrated that carbohydrates were also present in this part of the molecule. They behaved similarly to the CA-DTPA F(ab')2 derivative in other respects, but the kidney accumulation was lower at 72 and 120 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384100     DOI: 10.1007/bf00998159

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  18 in total

1.  Radiolabeling of monoclonal antibodies.

Authors:  J C Saccavini; J Bohy; J Bruneau
Journal:  Int J Rad Appl Instrum B       Date:  1986

2.  Preparation of F(ab')2 fragments from monoclonal mouse IgG1 suitable for use in radioimaging.

Authors:  R Kurkela; L Vuolas; P Vihko
Journal:  J Immunol Methods       Date:  1988-06-13       Impact factor: 2.303

3.  Purification of monoclonal antibodies raised against prostate-specific acid phosphatase for use in vivo in radioimaging of prostatic cancer.

Authors:  L Hakalahti; P Vihko
Journal:  J Immunol Methods       Date:  1989-02-08       Impact factor: 2.303

4.  Purification of human prostatic acid phosphatase by affinity chromatography and isoelectric focusing. Part I.

Authors:  P Vihko; M Kontturi; L K Korhonen
Journal:  Clin Chem       Date:  1978-03       Impact factor: 8.327

5.  Site-specifically modified 111In labelled antibodies give low liver backgrounds and improved radioimmunoscintigraphy.

Authors:  V L Alvarez; M L Wen; C Lee; A D Lopes; J D Rodwell; T J McKearn
Journal:  Int J Rad Appl Instrum B       Date:  1986

6.  90Y-labeled monoclonal antibodies for cancer therapy.

Authors:  L C Washburn; T T Hwa Sun; J E Crook; B L Byrd; J E Carlton; Y W Hung; Z S Steplewski
Journal:  Int J Rad Appl Instrum B       Date:  1986

7.  Immunoscintigraphic evaluation of lymph node involvement in prostatic carcinoma.

Authors:  P Vihko; M Kontturi; O Lukkarinen; P Martikainen; L Pelliniemi; J Heikkilä; R Vihko
Journal:  Prostate       Date:  1987       Impact factor: 4.104

8.  The effect of tumor CEA content and tumor size on tissue uptake of indium 111-labeled anti-CEA monoclonal antibody.

Authors:  V J Philben; J G Jakowatz; B G Beatty; W G Vlahos; R J Paxton; L E Williams; J E Shively; J D Beatty
Journal:  Cancer       Date:  1986-02-01       Impact factor: 6.860

9.  Radioimaging of the prostate and metastases of prostatic carcinoma with 99mTc-labelled prostatic acid phosphatase-specific antibodies and their Fab fragments.

Authors:  P Vihko; J Heikkilä; M Kontturi; L Wahlberg; R Vihko
Journal:  Ann Clin Res       Date:  1984

10.  Secretion into and elimination from blood circulation of prostate specific acid phosphatase, measured by radioimmunoassay.

Authors:  P Vihko; F H Schroeder; O Lukkarinen; R Vihko
Journal:  J Urol       Date:  1982-07       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.